Premium
Efficacy of enprofylline in acute airway obstruction
Author(s) -
Sandström T.,
Andersen J. R.,
Boethius G.,
Eriksson G.,
Hagman A.,
Helsted M.,
Lund B.,
Matsols H.,
Månsson T.,
Rosenhall L.
Publication year - 1991
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.1991.tb00541.x
Subject(s) - bronchodilation , medicine , anesthesia , regimen , airway obstruction , exacerbation , nausea , asthma , bronchodilator , airway
The efficacy and safety of different regiments of intravenously administered enprofylline, an anti‐asthma xanthine, were evaluated in a randomized open study, including 155 patients with acute exacerbation of obstructive long disease. The regimen 2.5 mg/kg i.v over 10 min was canceled after seven patients had been included, due to tow cases of hypotensive/vasovagal reactions. The regimens 2.0 mg/kg/20 min and 2.5 mg/kg/20 min were significantly more effective with regard to bronchodilation than 2.0 mg/kg/10 min (PEF Increase +35%+ 30% and +17% respectively). Nausea and headache were the most common side effects (16–33% and 23–33% of the patients respectively on different regimens) with the lowest frequency on 2.0 mg/kg/20 min Four additional hypotensive reactions occurred: one on each 2.0 mg/kg regimen and two on 2.5 mg/kg/20 min. The regimen 2.0 mg/kg/20 min was found to be the most favourable with regard to efficacy and side effects. Enprofylline i.v. was found to be an effective bronchodilating treatment of acute airway obstruction but the frequency of side effects has to be considered.